Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer [Phase 2]
This is a Phase 2 clinical trial evaluating subcutaneous atezolizumab for non-small cell lung cancer, sponsored by the University of Souther…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
A clinical trial evaluating whether plasma extracellular vesicle analysis can predict response to anti-PD-1/PD-L1 immunotherapy in non-small…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients [Phase 1]
A Phase 1 trial evaluating pembrolizumab with stereotactic body radiotherapy in metastatic non-small cell lung cancer was terminated, and th…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors [Phase 1]
Phase 1 clinical trial evaluating BL-B01D1 in patients with metastatic or unresectable non-small cell lung cancer and other solid tumors is …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
A retrospective multicenter study using T1CE/FLAIR MRI deep learning to predict EGFR/ALK driver status in brain metastases from non-small ce…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 dose-finding and dose-expansion study of OSE-279 in adults with advanced solid tumors or ly…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer [Phase 2]
This is a Phase 2 open-label randomized neoadjuvant trial evaluating nivolumab plus chemotherapy with or without sub-ablative SBRT in patien…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports a Phase Ib/II study of TCC1727 in combination therapy for advanced solid tumors, including non-small cell…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Atamparib in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for Atamparib in patients with advanced solid tumors, including non-small cell lung cancer with adenocarcinoma histolo…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Association of Different Tidal Volumes and Postoperative Pulmonary Complications
A clinical trial is studying the effect of different tidal volumes during thoracic surgery with one-lung ventilation on postoperative pulmon…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases [Phase 1]
A Phase 1 clinical trial update describes using Papaverine with stereotactic body radiotherapy for non-small cell lung cancer, currently act…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy [Phase 1]
Phase 1 clinical trial evaluating a vaccine therapy in combination with pembrolizumab for adults with various solid tumors that have failed …
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors [Phase 2]
Phase 2 trial update for HER3-DXd in locally advanced or metastatic solid tumors; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/Phase 2 study evaluating the combination of atezolizumab and pirfenidone in second-line and bey…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Expanded access program for Ulixertinib (BVD-523) in patients with advanced MAPK pathway-altered malignancies across multiple tumor types. T…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: A Study of KK2269 in Adult Participants With Solid Tumors [Phase 1]
Phase 1 study update for KK2269 in adults with solid tumors; the trial is currently recruiting. Indications include gastric adenocarcinoma, …
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update indicates that TH9619 is being studied in a Phase 1/2 trial for advanced solid tumors, with recruitment ongoing a…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Clinical trial evaluating the antitumor immune response after concurrent chemoradiotherapy and immunotherapy in non-resectable stage III non…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study.
This single-center real-world trial evaluates how surgical decisions for stage II-IIIB non-small cell lung cancer may change when comparing …
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib [Phase 2]
A Phase 2 clinical trial is evaluating trilaciclib to prevent chemotherapy-induced bone marrow suppression in advanced non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features [Phase 3]
Phase III randomized trial evaluating adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monother…